• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

siRNA 序列特异性稳定性的综合分析。

Comprehensive analysis of sequence-specific stability of siRNA.

机构信息

Institute of Molecular Medicine, Peking University, Beijing, China.

出版信息

FASEB J. 2010 Dec;24(12):4844-55. doi: 10.1096/fj.09-142398. Epub 2010 Aug 23.

DOI:10.1096/fj.09-142398
PMID:20732955
Abstract

Double-stranded small interfering RNAs (siRNAs) are important modulators of biological processes and hold great promise for therapeutic applications. However, serum processing of synthetic siRNAs is still largely unknown. To address this issue, serum degradation assays of 125 siRNAs were first performed in this study. Four siRNA categories of distinct serum stability were identified, including a group of siRNAs that were stable in their native form for both in vitro and in vivo assays. Fine mapping of the cleavage events occurring in serum treatment demonstrated that most occurred at two vulnerable sites, leading to a speculation that rational modification of these sites might protect most siRNAs from serum degradation. For proof of concept, an exhaustive siRNA modification study was performed. In addition to the consistent stabilization pattern revealed at these sites, our study further showed that a single modification made at the cleavage site stabilized the siRNAs to a large extent, highlighting the importance of these sites in siRNA degradation. In summary, the present study provided a comprehensive picture of serum processing of siRNA as well as a starting point for a rational siRNA modification strategy, both of which are of great importance to in vivo and therapeutic applications of siRNA.

摘要

双链小干扰 RNA(siRNAs)是生物过程的重要调节剂,在治疗应用方面具有很大的潜力。然而,合成 siRNAs 的血清处理在很大程度上仍不为人知。为了解决这个问题,本研究首先对 125 种 siRNA 的血清降解进行了测定。鉴定出了具有不同血清稳定性的 4 种 siRNA 类别,包括一组在体外和体内测定中以其天然形式稳定的 siRNA。对血清处理中发生的切割事件的精细定位表明,大多数切割发生在两个脆弱的位点,这使得人们推测对这些位点进行合理修饰可能会保护大多数 siRNA 免受血清降解。为了验证这一概念,进行了详尽的 siRNA 修饰研究。除了在这些位点揭示的一致稳定模式外,我们的研究还进一步表明,在切割位点进行单一修饰在很大程度上稳定了 siRNA,突出了这些位点在 siRNA 降解中的重要性。总之,本研究提供了 siRNA 血清处理的全面图景以及合理的 siRNA 修饰策略的起点,这两者对于 siRNA 的体内和治疗应用都非常重要。

相似文献

1
Comprehensive analysis of sequence-specific stability of siRNA.siRNA 序列特异性稳定性的综合分析。
FASEB J. 2010 Dec;24(12):4844-55. doi: 10.1096/fj.09-142398. Epub 2010 Aug 23.
2
Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication.稳定化短干扰RNA在乙型肝炎病毒复制小鼠模型中的活性
Hepatology. 2005 Jun;41(6):1349-56. doi: 10.1002/hep.20702.
3
Derivation and function of small interfering RNAs and microRNAs.小干扰RNA和微小RNA的衍生及功能
Virus Res. 2004 Jun 1;102(1):3-9. doi: 10.1016/j.virusres.2004.01.009.
4
Quantification of siRNAs in vitro and in vivo.体外和体内小干扰RNA(siRNA)的定量分析。
Methods Mol Biol. 2011;764:183-97. doi: 10.1007/978-1-61779-188-8_12.
5
Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo.利用解锁核酸(UNA)提高小干扰RNA(siRNA)在体外和体内的性能。
Mol Biosyst. 2010 May;6(5):862-70. doi: 10.1039/b918869j. Epub 2010 Feb 9.
6
Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing.小干扰RNA核酸酶稳定性对小干扰RNA介导的基因沉默的体外和体内动力学的影响。
Biotechnol Bioeng. 2007 Jul 1;97(4):909-21. doi: 10.1002/bit.21285.
7
Rational design and in vitro and in vivo delivery of Dicer substrate siRNA.Dicer底物小干扰RNA的合理设计及其体内外递送
Nat Protoc. 2006;1(2):508-17. doi: 10.1038/nprot.2006.72.
8
Optimization of transfection conditions and analysis of siRNA potency using real-time PCR.使用实时PCR优化转染条件并分析siRNA效力
Methods Mol Biol. 2011;764:199-213. doi: 10.1007/978-1-61779-188-8_13.
9
Short interfering RNA strand selection is independent of dsRNA processing polarity during RNAi in Drosophila.在果蝇的RNA干扰过程中,短干扰RNA链的选择与双链RNA加工极性无关。
Curr Biol. 2006 Mar 7;16(5):530-5. doi: 10.1016/j.cub.2006.01.061.
10
Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum.抑制核糖核酸酶A家族酶可防止血清中siRNA的降解及沉默活性丧失。
Biochem Pharmacol. 2006 Feb 28;71(5):702-10. doi: 10.1016/j.bcp.2005.11.015. Epub 2006 Jan 10.

引用本文的文献

1
Effect of Cyclodextrins Formulated in Liposomes and Gold and Selenium Nanoparticles on siRNA Stability in Cell Culture Medium.脂质体、金纳米颗粒和硒纳米颗粒中包封的环糊精对细胞培养基中siRNA稳定性的影响。
Pharmaceuticals (Basel). 2024 Oct 8;17(10):1344. doi: 10.3390/ph17101344.
2
Single therapeutic dose of an antiviral UL29 siRNA swarm diminishes symptoms and viral load of mice infected intranasally with HSV-1.单剂量治疗性抗病毒UL29 siRNA簇可减轻经鼻感染单纯疱疹病毒1型(HSV-1)小鼠的症状并降低病毒载量。
Smart Med. 2023 May 10;2(2):e20230009. doi: 10.1002/SMMD.20230009. eCollection 2023 May.
3
Applications of advances in mRNA-based platforms as therapeutics and diagnostics in reproductive technologies.
基于mRNA的平台在生殖技术中作为治疗和诊断手段的进展应用。
Front Cell Dev Biol. 2023 May 26;11:1198848. doi: 10.3389/fcell.2023.1198848. eCollection 2023.
4
A Fresh Look at the Potential of Cyclodextrins for Improving the Delivery of siRNA Encapsulated in Liposome Nanocarriers.重新审视环糊精在改善脂质体纳米载体包裹的小干扰RNA递送方面的潜力
ACS Omega. 2022 Jan 14;7(4):3731-3737. doi: 10.1021/acsomega.1c06436. eCollection 2022 Feb 1.
5
siRNA Design and GalNAc-Empowered Hepatic Targeted Delivery.siRNA 设计与 GalNAc 赋能的肝靶向递送。
Methods Mol Biol. 2021;2282:77-100. doi: 10.1007/978-1-0716-1298-9_6.
6
RNA-based therapeutics for colorectal cancer: Updates and future directions.基于 RNA 的结直肠癌治疗药物:最新进展及未来方向。
Pharmacol Res. 2020 Feb;152:104550. doi: 10.1016/j.phrs.2019.104550. Epub 2019 Dec 19.
7
Design Considerations for RNA Spherical Nucleic Acids (SNAs).RNA球形核酸(SNA)的设计考量
Bioconjug Chem. 2016 Sep 21;27(9):2124-31. doi: 10.1021/acs.bioconjchem.6b00350. Epub 2016 Aug 14.
8
RNA as a stable polymer to build controllable and defined nanostructures for material and biomedical applications.RNA作为一种稳定的聚合物,用于构建适用于材料和生物医学应用的可控且明确的纳米结构。
Nano Today. 2015 Oct 1;10(5):631-655. doi: 10.1016/j.nantod.2015.09.003.
9
Systemic Administration of siRNA via cRGD-containing Peptide.通过含cRGD肽进行小干扰RNA的全身给药。
Sci Rep. 2015 Aug 24;5:12458. doi: 10.1038/srep12458.
10
RNA/aTNA chimeras: RNAi effects and nucleases resistance of single and double stranded RNAs.RNA/人工合成tRNA嵌合体:单链和双链RNA的RNA干扰效应及核酸酶抗性
Molecules. 2014 Nov 4;19(11):17872-96. doi: 10.3390/molecules191117872.